Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIR143#12
- Development stage
- Preclinical
- Lead developer
- Gifu University
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
MIR143#12 is a chemically modified microRNA-143-3p (miR-143-3p) mimic developed to treat KRAS-mutant cancers. It is engineered for enhanced nuclease resistance and increased anti-cancer activity compared to unmodified miR-143. The drug acts by simultaneously silencing multiple nodes of the RAS signaling network, including KRAS, SOS1, AKT, and ERK. This broad suppression of the KRAS network induces apoptosis and inhibits cell growth more effectively than targeting KRAS alone, particularly in colorectal and pancreatic cancer models. Preclinical studies have also indicated that MIR143#12 may influence the tumor microenvironment by inducing neoangiogenesis while maintaining overall tumor growth suppression.
- Other names
- chemically modified MIR143-3pmiR-143-3p mimicmiR143-3p mimicmiR 143-3p mimic
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)Extracellular signal-regulated kinase 1/2 messenger RNAMAPK7 (ERK5)Kirsten rat sarcoma viral oncogene homolog mRNANRAS (Neuroblastoma RAS viral oncogene homolog)RREB1 (Ras responsive element binding protein 1)MAPK3 (Mitogen-activated protein kinase 1)KRAS (Kirsten rat sarcoma viral oncogene homolog)SOS1 (Son of sevenless homolog 1)
Beyond the preview
Go deeper on MIR143#12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIR143#12.